Changes in Hong Kong stocks | Dongguang Changjiang Pharmaceutical (01558) rose more than 7%, leading pharmaceutical stocks to the recent frequent incidence of respiratory diseases such as influenza
Pharmaceutical stocks continued to rise in the afternoon. As of press release, Dongguang Changjiang Pharmaceutical (01558) rose 6.8% to HK$9.27; Hehuang Pharmaceutical (00013) rose 4.87% to HK$30.15; Sansheng Pharmaceutical (01530) rose 3.77% to HK$7.43; and Shiyao Group (01093) rose 2.63% to HK$7.03.
Earnings Are Growing at 3SBio (HKG:1530) but Shareholders Still Don't Like Its Prospects
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market index fund. But the main game is to find enough winners to more than offset the lo
Bank of China Fund Zheng Ning: Optimistic about the pharmaceutical industry's reversal, in-hospital product-side companies, especially innovative drugs, are worth paying attention to
Recently, Bank of China Fund Zheng Ning said in an in-depth interview that in the next rise in the pharmaceutical industry, the hospital's product-side companies, especially innovative drugs, are expected to take the lead.
CITIC Construction Investment: Positive year-on-year growth in pharmaceutical revenue in the first three quarters favors prescription drugs, traditional Chinese medicine, etc.
The overall sector's revenue in the first three quarters of 2023 achieved positive year-on-year growth, and the growth rate declined in the third quarter. The growth rate slowed mainly due to increased compliance requirements, but the downturn was not overshadowed, and immediate demand and innovation drove the industry's Q3 revenue to continue to grow.
3SBio Secures Exclusive License to CStone's Anti-Tumor Drug in China
3SBio (HKG:1530) struck an exclusive licensing agreement to develop, manufacture and commercialize CStone Pharmaceuticals' (HKG:2616) anti-tumor medication nofazinlimab (CS1003) in mainland China. The
Painful Week for Individual Investors Invested in 3SBio Inc. (HKG:1530) After 5.4% Drop, Institutions Also Suffered Losses
Key Insights 3SBio's significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public 49% of the business is held by the top 25 shareh
Could The Market Be Wrong About 3SBio Inc. (HKG:1530) Given Its Attractive Financial Prospects?
3SBio (HKG:1530) has had a rough three months with its share price down 13%. However, stock prices are usually driven by a company's financial performance over the long term, which in this case look
3SBIO: 2023 INTERIM REPORT
CITIC Construction Investment: Innovative pharmaceutical companies are still optimistic about segments such as prescription drugs and medical devices on the high-value investment track
The Zhitong Finance App learned that CITIC Construction Investment released a research report stating that last week it focused on reviewing the mid-term business conditions of pharmaceutical companies and innovative pharmaceutical companies.
Sun Yuanyuan of Societe Generale Securities: Pharmaceuticals have bottomed out and the three most promising directions for the next six months or years
The Zhitong Finance App learned that recently, Sun Yuanyuan, chief analyst of the pharmaceutical industry at Societe Generale Securities, said that pharmaceuticals have bottomed out, and there are still great investment opportunities in the future. Now is a relatively good time to invest. Overall, both inside and outside the hospital showed a positive trend.
Is 3SBio (HKG:1530) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' So it might be obvious that you need to consider debt, whe
3SBio Reports 1H Results
3SBio's H1 Attributable Profit Rises, Beats EPS Estimates
3SBio's (HKG:1530) attributable profit increased to 980.6 million yuan, or 0.40 yuan per share, in the first half, from 966.9 million yuan, or 0.39 yuan per share, in the year-ago period, a Thursday f
3SBio Announces 2023 Interim Results: Over 20% Year-on-Year Growth, Continuous Improvement in Pipeline Value
Hong Kong August 25, 2023, PRNewswire/- 3SBio Pharma (01530.HK), a leading biopharmaceutical company in China, announced the 2023 interim results on 24 August 2023. In the first half of 2023, 3SBio achieved a total operating revenue of about RMB3,784 billion, up 22.3% over the same period last year; gross profit of about RMB3,202 million, an increase of 24.8% over the same period last year; normalized EBITDA RMB 1,518 billion, up 17.7% year-on-year; normalized motherhood net profit of about 1,191 million yuan, up 20.1% yoy
Read the 2023 Interim Report of Sansei Pharmaceutical (01530.HK) in one picture
On August 24, 2023, Sansheng Pharmaceutical (01530.HK), a leading biopharmaceutical company in China, announced its 2023 interim results. How to read the specific results in a picture.
3SBIO: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2023
With EPS Growth And More, 3SBio (HKG:1530) Makes An Interesting Case
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage
Sansheng Pharmaceutical (01530.HK) plans to hold a board meeting on August 24 to approve interim results
GLONGHUI, August 11丨Sansheng Pharmaceutical (01530.HK) announced that the company will hold a board meeting on August 24, 2023 (Thursday) to consider and approve the unaudited interim results of the company and its subsidiaries for the six months ended June 30, 2023 and their announcements, and consider the payment of interim dividends (if any).
3SBIO: NOTICE OF BOARD MEETING
Express News | 3SBio Hires Former JPMorgan Exec as CFO